At the time of writing, Quest Diagnostics, Inc. [DGX] stock is trading at $155.04, down -1.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DGX shares have gain 3.60% over the last week, with a monthly amount glided 0.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Quest Diagnostics, Inc. [NYSE: DGX] stock has seen the most recent analyst activity on October 23, 2024, when Robert W. Baird upgraded its rating to a Outperform and also boosted its price target to $182 from $157. On July 10, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $165 on the stock. Leerink Partners started tracking the stock assigning a Market Perform rating and suggested a price target of $135 on February 26, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $155 on February 07, 2024. Barclays started tracking with a Equal Weight rating for this stock on January 03, 2024, and assigned it a price target of $145. In a note dated December 12, 2023, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $140 to $160.
For the past year, the stock price of Quest Diagnostics, Inc. fluctuated between $121.60 and $160.95. Currently, Wall Street analysts expect the stock to reach $166.62 within the next 12 months. Quest Diagnostics, Inc. [NYSE: DGX] shares were valued at $155.04 at the most recent close of the market. An investor can expect a potential return of 7.47% based on the average DGX price forecast.
Analyzing the DGX fundamentals
According to Quest Diagnostics, Inc. [NYSE:DGX], the company’s sales were 9.54B for trailing twelve months, which represents an 8.41% jump. Gross Profit Margin for this corporation currently stands at 0.16% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.19 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 153.06 points at the first support level, and at 151.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 157.72, and for the 2nd resistance point, it is at 160.40.
Ratios To Look Out For
It is important to note that Quest Diagnostics, Inc. [NYSE:DGX] has a current ratio of 1.25. As well, the Quick Ratio is 1.17, while the Cash Ratio is 0.37. Considering the valuation of this stock, the price to sales ratio is 1.81, the price to book ratio is 2.55 and price to earnings (TTM) ratio is 20.81.
Transactions by insiders
Recent insider trading involved PREVOZNIK MICHAEL E, SVP & General Counsel, that happened on Aug 29 ’24 when 32551.0 shares were sold. SVP, Clinical Solutions, KUPPUSAMY KARTHIK completed a deal on Aug 28 ’24 to sell 1990.0 shares. Meanwhile, Officer PREVOZNIK MICHAEL E bought 32551.0 shares on Aug 29 ’24.
